BioCentury | Aug 12, 2019
Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

...to $260 million in clinical, regulatory and sales milestones in a deal that gives Jazz CX-8998...
...43; TNFRSF10B (DR5; TRAILR2; CD262) - Tumor necrosis factor receptor superfamily member 10b BioCentury Staff bavituximab (3G4, Tarvacin) CX-8998 Keytruda...
BioCentury | Oct 11, 2018
Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

...Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial...
...trial. CX-8998 is a calcium channel T-type blocker. On the Phase II trial's primary endpoint, CX-8998...
...outcome of the study." Papapetropoulos is EVP of R&D and CMO at Cavion. Cavion said CX-8998...
BioCentury | Oct 8, 2018
Clinical News

Cavion planning Phase III for essential tremor candidate despite Phase II miss

...Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial...
...trial. CX-8998 is a calcium channel T-type blocker. On the Phase II trial's primary endpoint, CX-8998...
...outcome of the study." Papapetropoulos is EVP of R&D and CMO at Cavion. Cavion said CX-8998...
BioCentury | Jan 6, 2017
Financial News

Cavion raises $26.1M series A

...million in "non-dilutive resources." This year, Cavion plans to start a Phase II trial of CX-8998...
...treat essential tremor. The candidate is an inhibitor of all Cav3 calcium channel isoforms. Jaime De Leon Cavion CX-8998...
Items per page:
1 - 4 of 4